Morrison, Anthony PPyle, MelissaGumley, AndrewSchwannauer, MatthiasTurkington, DouglasMacLennan, GraemeNorrie, JohnHudson, JemmaBowe, SamanthaFrench, PaulHutton, PaulByrne, RorySyrett, SuzyDudley, RobertMcLeod, Hamish JGriffiths, HelenBarnes, Thomas ReDavies, LindaShields, GemmaBuck, DeborahTully, SarahKingdon, David2019-03-292019-03-292019-02-28Morrison, A P, Pyle, M, Gumley, A, Schwannauer, M, Turkington, D, MacLennan, G, Norrie, J, Hudson, J, Bowe, S, French, P, Hutton, P, Byrne, R, Syrett, S, Dudley, R, McLeod, H J, Griffiths, H, Barnes, T R, Davies, L, Shields, G, Buck, D, Tully, S & Kingdon, D 2019, 'Cognitive-behavioural therapy for clozapine-resistant schizophrenia : the FOCUS RCT', Health Technology Assessment, vol. 23, no. 7, pp. 1-144. https://doi.org/10.3310/hta230701366-5278ORCID: /0000-0002-1039-5646/work/98038503http://hdl.handle.net/2164/12098Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 7. See the NIHR Journals Library website for further project information.1442027166engSDG 3 - Good Health and Well-beingANTIPSYCHOTIC-DRUGSCONFIRMATORY FACTOR-ANALYSISCOST-EFFECTIVENESSNEGATIVE-SYNDROME-SCALEPOSITIVE SYMPTOMSPSYCHOMETRIC PROPERTIESPSYCHOTIC SYMPTOMSQUALITY-OF-LIFERANDOMIZED CONTROLLED-TRIALWORKING-MEMORYR MedicineHealth PolicyNational Institute for Health Research (NIHR)RJournal article10.3310/hta23070http://www.scopus.com/inward/record.url?scp=85064731380&partnerID=8YFLogxK237